In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
The FDA has approved a triple test from Roche to simultaneously detect HIV, hepatitis C and hepatitis B in donated blood and blood products. It's the first test approved by the agency to simultaneously test for all three of these blood-borne diseases and is expected to reduce the necessary sample volume and the testing turnaround time.
Argos Therapeutics' HIV treatment failed to meet its main goal in a midstage trial, raising concerns about the company's platform technology and sending its shares spiraling downward.
Last year, India's Cipla forked over $500 million to get complete ownership of South Africa's Cipla Medpro. A new contract from the South African government for antiretroviral drugs sheds some light on the potential motivation for more than doubling its original offer to get the whole company.
Researchers at Harvard University have demonstrated that a nonsurgical injection of programmable biomaterial can assemble in vivo into a 3-D structure to attack cancer cells and help to prevent other infectious diseases such as HIV.
The National Institutes of Health recently awarded $20 million to a collaboration of researchers led by the Oak Crest Institute of Science to develop a novel intravaginal ring designed to prevent the spread of sexually transmitted HIV in women by delivering powerful combinations of antiretroviral drugs.
HIV/AIDS prevention can be difficult in countries with limited resources, especially when it comes to the millions of affected children who are less likely to tolerate antiretroviral drugs. In an effort to overcome this challenge, researchers at Penn State University have developed a delivery system for the antiretroviral Ritonavir that uses a protein in cow's milk for oral administration of the drug.
Investigators at Harvard say that they have successfully used CRISPR Cas gene-editing tools to come up with a new approach in curing HIV, a lethal virus that has claimed millions of lives over recent decades. And they're prepping for animal studies now to see if they can provide some preclinical proof-of-concept data to back up their lab experiment.
Investigators at Yerkes National Primate Research Center at Emory University may have found new evidence that dispels the theory that macrophages, a type of white blood cell, may harbor HIV for long periods of time, acting as a reservoir.
Researchers at the Salk Institute for Biological Studies have uncovered a protein that plays a role in active HIV replication, essentially acting as part of a switch to turn HIV-1, the most common type of HIV, from a dormant state to an active one.